Please use this identifier to cite or link to this item:
https://doi.org/10.1371/journal.pone.0153863
DC Field | Value | |
---|---|---|
dc.title | Cytochrome P4501A2 metabolizes 17?-estradiol to suppress hepatocellular carcinoma | |
dc.contributor.author | Ren J. | |
dc.contributor.author | Chen G.G. | |
dc.contributor.author | Liu Y. | |
dc.contributor.author | Su X. | |
dc.contributor.author | Hu B. | |
dc.contributor.author | Leung B.C.S. | |
dc.contributor.author | Wang Y. | |
dc.contributor.author | Ho R.L.K. | |
dc.contributor.author | Yang S. | |
dc.contributor.author | Lu G. | |
dc.contributor.author | Lee C.G. | |
dc.contributor.author | Lai P.B.S. | |
dc.date.accessioned | 2019-11-06T07:57:49Z | |
dc.date.available | 2019-11-06T07:57:49Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Ren J., Chen G.G., Liu Y., Su X., Hu B., Leung B.C.S., Wang Y., Ho R.L.K., Yang S., Lu G., Lee C.G., Lai P.B.S. (2016). Cytochrome P4501A2 metabolizes 17?-estradiol to suppress hepatocellular carcinoma. PLoS ONE 11 (4) : e0153863. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0153863 | |
dc.identifier.issn | 19326203 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/161572 | |
dc.description.abstract | Hepatocellular carcinoma (HCC) occurs more frequently in men than in women. It is commonly agreed that estrogen plays important roles in suppressing HCC development, however, the underlying mechanism remains largely unknown. Since estrogen is mainly metabolized in liver and its metabolites affect cell proliferation, we sought to investigate if the liver-specific cytochrome P450 1A2 (CYP1A2) mediated the inhibitory effect of estrogen on HCC. In this study, the expression of estrogen-metabolizing enzyme CYP1A2 was determined in HCC tissues and cell lines. Cell proliferation and apoptosis were assessed in cells with or without CYP1A2 overexpression. The levels of 17?-estradiol (E2) and its metabolite 2-methoxyestradiol (2-ME) were determined. A xenograft tumor model in mice was established to confirm the findings. It was found that CYP1A2 expression was greatly repressed in HCC. E2 suppressed HCC cell proliferation and xenograft tumor development by inducing apoptosis. The inhibitory effect was significantly enhanced in cells with CYP1A2 overexpression, which effectively conversed E2 to the cytotoxic 2-ME. E2 in combination with sorafenib showed an additive effect on HCC. The anti-HCC effect of E2 was not associated with estrogen receptors ER? and ER? as well as tumor suppressor P53 but enhanced by the approved anti-HCC drug sorafenib. In addition, HDAC inhibitors greatly induced CYP1A2 promoter activities in cancer cells, especially liver cancer cells, but not in non-tumorigenic cells. Collectively, CYP1A2 metabolizes E2 to generate the potent anti-tumor agent 2-ME in HCC. The reduction of CYP1A2 significantly disrupts this metabolic pathway, contributing the progression and growth of HCC and the gender disparity of this malignancy. © 2016 Ren et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Unpaywall 20191101 | |
dc.subject | 2 methoxyestradiol | |
dc.subject | catechol methyltransferase | |
dc.subject | cytochrome P450 1A2 | |
dc.subject | cytochrome P450 3A4 | |
dc.subject | estradiol | |
dc.subject | protein p53 | |
dc.subject | sorafenib | |
dc.subject | 2-methoxyestradiol | |
dc.subject | carbanilamide derivative | |
dc.subject | CYP1A2 protein, human | |
dc.subject | cytochrome P450 1A2 | |
dc.subject | estradiol | |
dc.subject | estrogen | |
dc.subject | estrogen receptor | |
dc.subject | estrogen receptor alpha | |
dc.subject | estrogen receptor beta | |
dc.subject | nicotinamide | |
dc.subject | protein p53 | |
dc.subject | animal experiment | |
dc.subject | animal model | |
dc.subject | animal tissue | |
dc.subject | apoptosis | |
dc.subject | Article | |
dc.subject | cancer growth | |
dc.subject | cancer incidence | |
dc.subject | cancer inhibition | |
dc.subject | cell proliferation | |
dc.subject | clinical article | |
dc.subject | concentration (parameters) | |
dc.subject | controlled study | |
dc.subject | correlational study | |
dc.subject | cytotoxicity | |
dc.subject | female | |
dc.subject | hormone metabolism | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | human tissue | |
dc.subject | liver carcinogenesis | |
dc.subject | liver cell carcinoma | |
dc.subject | male | |
dc.subject | mouse | |
dc.subject | nonhuman | |
dc.subject | protein expression | |
dc.subject | protein function | |
dc.subject | protein protein interaction | |
dc.subject | sex difference | |
dc.subject | upregulation | |
dc.subject | analogs and derivatives | |
dc.subject | animal | |
dc.subject | Bagg albino mouse | |
dc.subject | Carcinoma, Hepatocellular | |
dc.subject | drug effects | |
dc.subject | liver | |
dc.subject | Liver Neoplasms | |
dc.subject | metabolism | |
dc.subject | nude mouse | |
dc.subject | tumor cell line | |
dc.subject | Animals | |
dc.subject | Apoptosis | |
dc.subject | Carcinoma, Hepatocellular | |
dc.subject | Cell Line, Tumor | |
dc.subject | Cell Proliferation | |
dc.subject | Cytochrome P-450 CYP1A2 | |
dc.subject | Estradiol | |
dc.subject | Estrogen Receptor alpha | |
dc.subject | Estrogen Receptor beta | |
dc.subject | Estrogens | |
dc.subject | Humans | |
dc.subject | Liver | |
dc.subject | Liver Neoplasms | |
dc.subject | Male | |
dc.subject | Mice | |
dc.subject | Mice, Inbred BALB C | |
dc.subject | Mice, Nude | |
dc.subject | Niacinamide | |
dc.subject | Phenylurea Compounds | |
dc.subject | Receptors, Estrogen | |
dc.subject | Tumor Suppressor Protein p53 | |
dc.type | Article | |
dc.contributor.department | BIOCHEMISTRY | |
dc.description.doi | 10.1371/journal.pone.0153863 | |
dc.description.sourcetitle | PLoS ONE | |
dc.description.volume | 11 | |
dc.description.issue | 4 | |
dc.description.page | e0153863 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1371_journal_pone_0153863.pdf | 3.99 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License